Purpose: Tc-99m-methoxyisobutylisonitrile (MIBI) accumulates in only viable cells. In patients with bone and soft tissue sarcomas, preoperative chemotherapy is essential and the early prediction of the tumor response to chemotherapy would be beneficial for the planning of treatment strategy. The purpose of this study was to assess whether the change of Tc-99m-MIBI images from the prechemotherapy state to the early to midportion of chemotherapy can predict the final histopathological tumor response as accurately as the change of imaging after completion of chemotherapy. Methods: Seventy-three patients with bone and soft tissue sarcomas underwent Tc-99m-MIBI scintigraphy before chemotherapy and at least 2 times after the second or third or fifth course of chemotherapy. The changes of the tracer uptake (⌬UR) and perfusion (⌬PI) from prechemotherapy to postchemotherapy were compared with histologic response. Results: The sensitivity, specificity, and accuracy for the prediction of effective chemotherapy in ⌬PI were 88%, 83%, 85% after second, 85%, 72%, 78% after third, and 81%, 71%, 76% after 5th chemotherapy, and those in ⌬UR were 88%, 83%, 85% after 2nd, 85%, 92%, 89% after 3rd, and 94%, 77%, 85% after fifth chemotherapy, respectively. The area under the receiver operator characteristic curve of the ⌬PI after second, third, and fifth chemotherapy were similarly good (0.842, 0.858, 0.811, respectively) and those of ⌬UR were similarly excellent (0.915, 0.936, 0.931, respectively).
I
n patients with bone and soft tissue sarcomas, the combination of aggressive chemotherapy before surgical intervention and limb-sparing surgery permits excellent quality of life and dramatic improvement of the prognosis. 1 The accurate evaluation of chemotherapeutic effects is essential for a proper treatment strategy because a good response to preoperative chemotherapy is crucial to limb-sparing surgery. [2] [3] [4] In addition, early prediction of the tumor response to chemotherapy during preoperative chemotherapy would be beneficial for the planning of treatment strategy. Furthermore, noninvasive and quantitative assessment of tumor response to chemotherapy may provide prognostic information that could be useful for subsequent patient's management, because a good pathologic response to chemotherapy has been proved to be a predictor of good prognosis in osteosarcoma. 5, 6 Recently, there has been growing interest in using Tc-99m-hexakis-2-methoxyisobutylisonitrile (MIBI), used as a myocardial perfusion imaging agent, for tumor imaging including bone and soft-tissue tumors. [7] [8] [9] As a tumor imaging agent Tc-99m-MIBI has unique characteristics. Administration of high radionuclide activity permits radionuclide angiography, which provides information of tumor blood flow. After Tc-99m-MIBI accumulation in the tumor, the degree of washout of the tracer from the tumor reflects P-glycoprotein overexpression which implies multidrug resistance. 10, 11 In addition, several studies have revealed that the change of Tc-99m-MIBI uptake from prechemotherapy to postchemotherapy could reflect the chemotherapeutic effect in patients with bone sarcomas. 8, [12] [13] [14] However, there has been no report that investigated whether Tc-99m-MIBI imaging performed during preoperative chemotherapy as well as performed after the completion of chemotherapy can equally well predict final tumor response to preoperative chemotherapy.
Therefore, the purpose of this study was to assess whether the combination of Tc-99m-MIBI scintigraphy performed before and in the early to middle of the preoperative chemotherapy can predict final histopathological tumor response to chemotherapy without deterioration of the diagnostic accuracy compared with the combination of the imaging performed before chemotherapy and after the final cycle of chemotherapy in bone and soft tissue sarcomas.
MATERIALS AND METHODS

Patients
Seventy-three patients (54 men and 19 women; age range, 7-74 years, average age, 28.8 Ϯ 18 years) with various bone and soft-tissue sarcomas proven pathologically in specimens obtained by biopsy at pretreatment and operation after chemotherapy were recruited in this study, and all gave informed consent to participate in this study. There were 36 osteosarcomas (28 osteoblastic type, 5 chondroblastic type, 2 fibroblastic type, and 1 small cell osteosarcoma), 7 malignant fibrous histiocytomas (5 pleomorphic type, 1 spindle cell type, 1 myxoid type), 7 liposarcomas (6 myxoid liposarcomas and 1 pleomorphic liposarcoma), 6 Ewing sarcomas, 4 synovial sarcomas, 3 chondrosarcomas (2 mesenchymal chondrosarcomas and 1 extraskeletal myxoid chondrosarcoma), 3 rhabdomyosarcomas, 2 angiosarcomas, 2 leiomyosarcomas, 1 malignant schwannoma, 1 alveolar soft part sarcoma, and 1 malignant giant cell tumor. Sixty-three lesions were located in the extremities, 5 were located in the pelvic area, 2 were located at the shoulder, 2 were in ribs, 1 was at the axilla. Forty-six tumors were located in bone and 27 were in soft tissue.
Patients received 5 cycles of preoperative chemotherapy at intervals of 2 to 3 weeks. In each chemotherapy cycle, cisplatin (120 mg/m 2 ) was continuously infused through the intra-arterial catheter for 1 to 2 hours followed by 48 hours of continuous infusion of doxorubicin (60 mg/m 2 ) and 72 hours infusion of caffeine.
15,16
Study Protocol and Tc-99m-MIBI Scintigraphy
The study protocol is shown in Figure 1 . All patients underwent imaging with Tc-99m-MIBI at least 3 times. Before chemotherapy all patients underwent imaging with Tc-99m-MIBI (n ϭ 73), and after 1 week of the completion of the 2 (n ϭ 20) or 3 (n ϭ 69) or 5 cycles (n ϭ 66) of chemotherapy, the same radionuclide imaging procedures were performed. After completion of the 5 cycles of chemotherapy, surgery was performed. Then the scintigraphic predictive outcome for the chemotherapeutic effect was assessed in comparison with the results of the postoperative histologic examination.
Radionuclide angiography was performed after bolus injection of 600 to 740 MBq (16.2-20 mCi) of Tc-99m-MIBI with a gamma camera equipped with a low energy high-resolution parallelhole collimator. Data were acquired every 2 seconds for 2 minutes. Then, planar 2-minute Tc-99m-MIBI imaging of the lesion was obtained at 15 minutes after radionuclide administration with 256 ϫ 256 matrices.
Image Analysis
In the quantitative analysis of the prechemotherapeutic image, a manual region of interest (ROI) was set on the lesion and an automatically generated symmetrical ROI was set on the contralateral normal area as a background. When tumor Tc-99m-MIBI uptake was weak, the ROI of the tumor was delineated carefully to cover the whole lesion by referring to the computed tomography or magnetic resonance image. In the analysis of the images obtained after 2, 3, or 5 cycles of chemotherapy, tumor ROI was newly set to cover the whole lesion as described above. Therefore, the ROI size was changed depending on the size of the tumor. When the tumor uptake of radionuclide disappeared completely the same ROI delineated at prechemotherapy was applied to calculate the indices.
Tc-99m-MIBI uptake ratios (UR) were calculated by dividing the count density of the lesion by that of the background ROI. For the prediction of the chemotherapeutic effect, the percent reduction of uptake ratio (⌬UR) was calculated as follows:
/prechemotherapy UR͔ The perfusion index (PI) was obtained by radionuclide angiography with Tc-99m-MIBI. Using the same ROI set to calculate the uptake ratio, the time-activity curve of each ROI was generated, and the PI was determined by dividing the peak count of the arterial phase of the lesion by that of the background ROI. When a peak count was not obtained, the time activity curve always showed a shoulder point, which was the flexion point between the rapid count increase due to the arterial phase and steady state or gradual count increase due to Tc-99m-MIBI accumulation in the lesion and normal tissue. Therefore, the count of the flexion point of the time activity curve was used to calculate the PI. Percent reduction of perfusion index (⌬PI) was also calculated to predict the response to chemotherapy by the following formula:
Assessment of the Chemotherapeutic Effect by Histopathology
After 5 cycles of chemotherapy surgical resection of the tumor was performed. Postoperative histologic assessment was performed in all patients to evaluate the response of the tumor to chemotherapy. Histologic grading of the effect of chemotherapy was determined based on the degree of viable cellularity and necrosis in the largest slice of the resected tumor. 5 Grade IV (100% necrosis) and grade III (90% Յ to Ͻ100% necrosis) response were defined as a good response to chemotherapy (effective chemotherapy). Grade II (50% Ͻ to Ͻ90% necrosis) and grade I (Յ50% necrosis) responses were defined as poor response.
Statistics
Values are expressed as the mean Ϯ SD. Differences in PIs and URs, and ⌬PIs and ⌬URs between good and poor response were analyzed by the student t test using the software JMP-5.0.1J for Macintosh computer. To appraise the discrimination abilities of the ⌬PIs and ⌬URs for the prediction of effective chemotherapy, receiver operator characteristic (ROC) curves were generated, and the areas under the curves (A z ) were calculated. The differences between the areas under the 2 ROC curves were examined using the 1-tailed paired t test. 17, 18 The optimal cutoff levels were identified as each index value minimizing the total number of false results.
19 P Ͻ 0.05 was considered statistically significant. ROC analysis was performed using the software ROCKIT 0.9B (free software developed by Charles E. Metz, PhD for Macintosh computer).
17,18
RESULTS
Postoperative histologic examination of the resected tumors demonstrated good response in 33 patients and poor response in 40 patients. Good responders included 20 osteosarcomas, 3 malignant fibrous histiocytomas, 2 liposarcomas, 3 Ewing sarcomas, 1 synovial sarcomas, 1 rhabdomyosarcoma, 1 leiomyosarcoma, 1 malignant schwannoma, and 1 malignant giant cell tumor. Poor responders included 16 osteosarcomas, 4 malignant fibrous histiocytomas, 5 FIGURE 1. Study protocol. Tc-99m-MIBI scintigraphy was performed before chemotherapy in all patients, and at least 2 scintigraphic studies were performed after 2, 3, or 5 cycle of chemotherapy. The change of perfusion index and uptake ratio from prechemotherapy to after each chemotherapy cycle were compared with the histopathological response to chemotherapy.
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Prediction of Chemotherapeutic Effect by Tc-99m-MIBI liposarcomas, 3 Ewing sarcomas, 3 synovial sarcomas, 3 chondrosarcomas, 2 rhabdomyosarcomas, 2 angiosarcomas, 1 leiomyosarcoma, and 1 alveolar soft part sarcoma. All lesions showed significant tracer uptake. Accordingly, ROIs could be set without difficulty. In 2 patients after 3 cycles of chemotherapy and in 1 patient after 5 cycles of chemotherapy, PI of Tc-99m-MIBI was not calculated because of poor bolus infusion of the radionuclide.
Before preoperative chemotherapy, there are no differences between the patients with good and poor response in PI (3.97 Ϯ 2.51 and 3.38 Ϯ 1.68, respectively, P ϭ ns) and UP (2.83 Ϯ 0.93 and 2.74 Ϯ 1.38, respectively, P ϭ ns). After 2, 3, and 5 cycles of chemotherapy, in patients with good response, PI decreased to 1.81 Ϯ 0.61 (P Ͻ 0.01), 1.97 Ϯ 1.25 (P Ͻ 0.01), and 1.51 Ϯ 0.76 (P Ͻ 0.01), respectively, and UR also decreased to 1.56 Ϯ 0.46 (P Ͻ 0.01), 1.58 Ϯ 0.51 (P Ͻ 0.01), and 1.34 Ϯ 0.46 (P Ͻ 0.01), respectively. In patients with poor response, after 2, 3, and 5 cycles of chemotherapy, both PI (3.88 Ϯ 2.17, 3.70 Ϯ 2.77, 2.92 Ϯ 2.48, respectively) and UR (2.64 Ϯ 1.14, 2.61 Ϯ 1.22, 2.19 Ϯ 1.02, respectively) did not change significantly. Consequently, after 2, 3, and 5 cycles of chemotherapy, good responders demonstrated lower PI (P Ͻ 0.05, P Ͻ 0.01, P Ͻ 0.01, respectively) and lower UR (P Ͻ 0.05, P Ͻ 0.01, P Ͻ 0.01, respectively) than poor responders.
The ⌬PI after 2 cycles of chemotherapy in patients with good and poor response were 36% Ϯ 23% and Ϫ12% Ϯ 42% (P Ͻ 0.01), respectively ( Fig. 2A) . The ⌬PIs after 3 and 5 cycles of chemotherapy in patients with good and poor response were 45% Ϯ 27% and Ϫ8.3% Ϯ 50% (P Ͻ 0.0001), respectively (Fig. 2B) , and 55 Ϯ 22% and 19% Ϯ 37% (P Ͻ 0.0001), respectively (Fig. 2C) . The ⌬UR obtained after 2 cycles of chemotherapy in patients with good and poor response were 34% Ϯ 16% and Ϫ8% Ϯ 32% (P ϭ 0.005), respectively (Fig. 3A) , and those after 3 and 5 cycles of chemotherapy were 43% Ϯ 14% and Ϫ0.7% Ϯ 39% (P Ͻ 0.0001), respectively (Fig. 3B ) and 52% Ϯ 13% and 15% Ϯ 27% (P Ͻ 0.0001), respectively (Fig. 3C) .
The ROC curves for the predictability of effective chemotherapy of the ⌬PI and ⌬UR obtained after 2, 3, and 5 cycles of chemotherapy are shown in Figure 4 . The A z of the ⌬PI after 2, 3, and 5 cycles of chemotherapy were 0.842, 0.858, and 0.811, respectively, and there were no significant differences among the values (P ϭ 0.13-0.49). The A z of the ⌬UR after 2, 3, and 5 cycles of chemotherapy were 0.915, 0.936, and 0.931, respectively, and there were no significant differences among the values (P ϭ 0.15-0.31). When A z of the ⌬PI and ⌬UR in each cycles of chemotherapy is compared, A z of the ⌬PI is lower than that of ⌬UR in every scintigraphic timing but only statistically significant after 5 cycles of chemotherapy (2 cycle: P ϭ 0.16, 3 cycle: P ϭ 0.063, 5 cycle: P ϭ 0.0031).
The optimal thresholds obtained by ROC analysis, sensitivity, specificity, accuracy, positive and negative predictive values of each index obtained after 2, 3, and 5 cycles after chemotherapy were summarized in Table 1 . The accuracy of ⌬PI after 2, 3, and 5 cycles after chemotherapy was 85%, 78%, 76%, respectively, and that of ⌬UR after 2, 3, and 5 cycles after chemotherapy was 85%, 89%, 85%, respectively.
On the contrary, the accuracy of PI after 2, 3, and 5 cycles after chemotherapy was 70%, 69%, 70%, respectively, and that of UR after 2, 3, and 5 cycles after chemotherapy was 70%, 69%, 72%, respectively.
Representative cases are shown in Figure 5 (good responder) and Figure 6 (poor responder).
DISCUSSION
The present study demonstrated that the combination of the Tc-99m-MIBI scintigraphies performed before chemotherapy and in the early to middle of preoperative-chemotherapy (after the second and third cycle) as well as after the final cycle of chemotherapy (fifth cycle) can accurately predict the final response to chemotherapy which was proved by histopathology after 5 cycles of chemotherapy and operation. Based on the ROC analysis, both the performance of ⌬PI and ⌬UR for the prediction of the chemotherapeutic effect were similarly good after 2, 3, and 5 cycles of chemotherapy. Therefore, accurate prediction of the chemotherapeutic effect can be possible during the early to middle of chemotherapy. However, when ⌬PI and ⌬UR were compared, the predictive performance of ⌬UR tended to be better than that of ⌬PI after 2 and 3 cycles of therapy and significantly better after the final cycle of preoperative chemotherapy. 
FIGURE 5.
A 50-year-old woman with pleomorphic malignant fibrous histiocytoma of the left shoulder. Before chemotherapy, radionuclide angiography with Tc-99m-MIBI demonstrated marked increase in tumor blood flow. Anterior chest image obtained 15 minutes after the tracer injection showed intense accumulation of Tc-99m-MIBI in the left shoulder. After 2 cycles of chemotherapy, tumor blood flow and Tc-99m-MIBI uptake decreased dramatically. After 3 and 5 cycles of chemotherapy, no significant increase in tumor blood flow and Tc-99m-MIBI uptake were observed. All these findings implied a good response to chemotherapy. Wide resection of tumor was performed after 5 cycles of chemotherapy. Pathologic study of the resected tumor specimen revealed no viable tumor cells.
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On the contrary, the diagnostic accuracies for the prediction of chemotherapeutic effect of PI and UR itself after 2, 3, and 5 cycles of chemotherapy were 69% to 72%, and those were inferior to that of ⌬PI and ⌬UR (76%-89%, Table 1 ).
Tc-99m-MIBI was introduced primarily as a myocardial perfusion imaging agent to replace Tl-201. Tc-99m-MIBI has lipophilic cationic properties, accumulating largely in mitochondria by its negative transmembrane potential. Moreover, its accumulation depends on cell viability and metabolic status in myocardial cells. 20 -22 Like myocardial cells, human carcinoma cells accumulate Tc-99m-MIBI by depending on the mitochondria and plasma membrane potentials. 23, 24 In addition, radionuclide angiography with a sufficient dose at the administration of the tracer can permit evaluation of the tumor blood flow. Accordingly, Tc-99m-MIBI scintigraphy provides integrated information of the tumor blood flow and tracer uptake which reflect tumor viability and metabolic status.
For the evaluation of the tumor response to preoperative chemotherapy, several modalities are performed such as CT, MRI, angiography, ultrasonography, and radionuclide imaging. Conventional angiography with contrast medium can observe tumor blood flow. Although, it can offer precise morphology of tumor vasculature, quantification of the tumor blood flow is somewhat difficult compared with radionuclide angiography. CT and MRI can precisely evaluate the tumor size. However, they cannot evaluate tumor viability and metabolic status so precisely even with contrast enhancement because fibrotic changes, inflammatory changes, or granulation tissue secondary to tumor necrosis after chemotherapy could be enhanced. Dynamic contrast-enhanced MRI provides information about tissue perfusion, vascular permeability, microvessel density, 25 and may differentiate viable tumor tissue from reparative tissue. Several parameters by mathematical quantification of the dynamic data permit prediction of the chemotherapeutic response after the completion of the preoperative chemotherapy. 26 However, early prediction of the chemotherapeutic effect by dynamic MRI remains to be elucidated. 27, 28 The parameter calculated by dynamic MRI might mainly reflect tumor perfusion and might be similar to that obtained by radionuclide angiography with Tc-99m-labeled tracers. 28 Color Doppler ultrasound also could predict chemotherapeutic response by assessing the change of tumor blood supply and intratumoral blood flow after chemotherapy. 29 The method is relatively simple but further evaluation would be warranted including the issue of reproducibility. Several FDG-PET studies have also demonstrated the efficacy in the prediction of the effect of chemotherapy at the end of preoperative chemotherapy, 30 -34 however, sensitive FDG accumulation in chemotherapy induced inflammation or therapy-related fibrous tissue has impaired the diagnostic accuracy in some cases. [31] [32] [33] Unfortunately, there has been no report in terms of the early prediction of preoperative chemotherapy using FDG PET in bone and soft tissue sarcomas.
In a previous study with 12 osteosarcoma patients, reduction of Tc-99m-MIBI uptake after completion of chemotherapy roughly correlated with the histologic response. 35 Other studies with 28 bone sarcoma patients and 68 patients with bone and soft tissue sarcoma demonstrated good correlation between the reduction of Tc-99m-MIBI uptake after 3 or 4 cycles of chemotherapy and % necrosis of the tumor 36 and good predictability of tumor response to chemotherapy. 14 In the present study, in both bone and soft tissue sarcomas, reduction of tumor perfusion and Tc-99m-MIBI uptake in the early to middle of chemotherapy as well as after the final cycle of chemotherapy can predict the final histologic tumor response to chemotherapy. In the clinical setting, a precise diagnostic method for the assessment of the chemotherapeutic effect at the earliest possible time after initiation of chemotherapy would be preferable. Our current study demonstrated that early imaging could permit precise estimation of the chemotherapeutic effect after 2 or 3 cycles of preoperative chemotherapy as accurately as after the final cycle of therapy, suggesting that the method may have an impact on modification of the neoadjuvant chemotherapy protocol, on patient selection for the performance and timing of limb-sparing surgery, and on the selection of postoperative chemotherapy regimens. MIBI has been proved to be the one of the substrates of P-glycoprotein, a product of the human multidrug resistance gene and multidrug resistance-related protein. 37, 38 It has been proven that Tc-99m-MIBI once accumulated in tumor cells would be washed out from the cells by P-glycoprotein and the delayed Tc-99m-MIBI uptake was related to P-glycoprotein expression, while early uptake was not. 10 Accordingly, early Tc-99m-MIBI uptake seems to reflect tumor viability more properly than delayed uptake. Therefore, as a marker of tumor viability, we analyzed only Tc-99m-MIBI uptake in the early image obtained at 15 minutes after tracer injection.
For the assessment of tumor perfusion and Tc-99m-MIBI uptake, tumor ROI was set in each image before and after chemotherapy independently, ie, a new ROI was delineated after chemotherapy if tumor size changed to cover the whole tumor more precisely instead of using the same ROI used before chemotherapy. This is because we assessed the histologic grading of the chemotherapeutic effect based on the degree of cellularity and necrosis in the largest slice of the resected tumor as a gold standard of tumor response to chemotherapy. Accordingly ROI modification along with the change of the tumor size may reflect more precisely the tumor viability based on the histopathological examination.
FIGURE 6.
A 16-year-old male with osteosarcoma of the right distal femur. Before chemotherapy, radionuclide angiography with Tc-99m-MIBI demonstrated a marked increase in tumor blood flow and intense Tc-99m-MIBI uptake. After 2, 3, and 5 cycles of chemotherapy, tumor blood flow and tumor uptake of Tc-99m-MIBI were still increased. All of these findings implied a poor response to chemotherapy. After 5 cycles of chemotherapy, resection of the tumor was performed and the pathologic study of the resected tumor specimen revealed Յ50% tumor necrosis.
